Biotechnology remains one of the most dynamic corners of the equity market, offering exposure to innovation in drug development, gene editing, and molecular diagnostics. Investors evaluating this space often weigh two popular vehicles: ARKG (ARK Genomic Revolution ETF) and XBI (SPDR S&P Biotech ETF). Although both target healthcare innovation, they differ sharply in construction, cost, and risk profile. This stock comparison examines their relative performance and market positioning, helping both long-term investors and active traders assess which fund better aligns with their objectives in the current environment.
ARKG, the ARK Genomic Revolution ETF, is an actively managed fund advised by ARK Investment Management. It concentrates on companies tied to the "genomics revolution," spanning gene editing, targeted therapeutics, molecular diagnostics, and synthetic biology. Because it is actively managed, its holdings are chosen by portfolio managers rather than an index, and it typically holds a focused roster of roughly 30 to 50 names.
In recent weeks, ARKG has exhibited above-average volatility, reflecting both its growth-oriented mandate and its concentrated exposure. Top positions have included names such as 10x Genomics (TXG), Twist Bioscience (TWST), Tempus AI (TEM), and CRISPR Therapeutics (CRSP). Sentiment has been shaped by a mix of favorable clinical and diagnostic data alongside headwinds tied to research funding dynamics and the market's shifting appetite for long-duration, unprofitable growth companies. The fund's higher expense ratio of 0.75% is a further consideration for cost-conscious investors.
XBI, the SPDR S&P Biotech ETF, is a passively managed fund that tracks the S&P Biotechnology Select Industry Index. Unlike market-cap-weighted funds, XBI uses a modified equal-weight methodology, giving smaller and mid-sized biotech companies a more meaningful footprint relative to large-cap leaders. This structure typically results in a portfolio of well over 100 holdings.
Recent market activity has shown XBI participating in the broader biotech recovery, supported by deal activity, clinical readouts, and renewed interest in the sector. Its equal-weight approach helps temper the influence of any single stock, which has historically translated into a somewhat smoother return profile than more concentrated peers. With an expense ratio of 0.35%, XBI also carries a lower cost burden, an attribute many investors weigh when evaluating relative performance over the long term.
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across a wide range of sectors and styles. These bots differ in trading strategy, timeframe, performance statistics, and the specific set of tickers they monitor. Only the strongest and most suitable strategies for current market conditions are featured in the curated Trending AI Robots section, where visitors can review select bots with documented performance metrics and distinct approaches. For traders who prefer systematic, data-driven methods over discretionary decisions, exploring this page offers a practical way to see which automated strategies are currently generating notable signals. Discover the Trending AI Robots to evaluate which bots may align with your trading approach.
The clearest contrast between these two funds lies in their construction philosophy. ARKG is active, thematic, and concentrated, betting heavily on genomic innovation and accepting the volatility that comes with high-conviction positions. XBI is passive, broad, and equal-weighted, spreading risk across the full biotechnology spectrum from large established players to early-stage developers.
From a cost standpoint, XBI holds an advantage at 0.35% versus ARKG's 0.75%. On risk, ARKG has historically posted deeper drawdowns and higher volatility, while XBI's equal-weight design offers more balanced sector exposure. In terms of momentum, both funds have benefited from improving biotech sentiment, but XBI's broader base has generally produced more consistent trend behavior, whereas ARKG's returns can swing more sharply on developments affecting a handful of core holdings.
Weighing trend consistency, stability, cost, and relative positioning, Tickeron's AI would currently favor XBI. Its equal-weight, broadly diversified structure tends to generate a steadier trend profile and lower single-stock risk than ARKG's concentrated genomics exposure. While ARKG can outperform during sharp genomics rallies, its higher volatility and deeper historical drawdowns make it a less consistent candidate under current conditions. This assessment is probabilistic and based on observable factors rather than a definitive prediction of future returns.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARKG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
ARKG moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARKG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 249 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
| ARKG | XBI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Advances ODDS (%) | 13 days ago 90% | 13 days ago 90% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 85% |
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -5.64% | ||
| DNA - ARKG | 62% Loosely correlated | -9.02% | ||
| FATE - ARKG | 60% Loosely correlated | -9.01% | ||
| PHR - ARKG | 59% Loosely correlated | -3.88% | ||
| EDIT - ARKG | 59% Loosely correlated | -4.09% | ||
| BFLY - ARKG | 58% Loosely correlated | -7.69% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRTY | 33.09 | 2.56 | +8.39% |
| ProShares UltraPro Short Russell2000 (SRTY) | |||
| FMHI | 45.87 | 0.04 | +0.10% |
| First Trust Municipal High Income ETF (FMHI) | |||
| GLO | 5.06 | -0.14 | -2.69% |
| Clough Global Opportunities Fund | |||
| LBAY | 26.92 | -0.95 | -3.42% |
| Leatherback Long/Short Alternative Yield ETF (LBAY) | |||
| MEGX | 16.09 | -2.96 | -15.53% |
| Corgi U.S. Mega-Cap Growth 2x Daily ETF (MEGX) | |||